Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Evaluation of Serum Preptin Levels in Patients With Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age and is strongly associated with insulin resistance and metabolic dysfunction. Preptin is a pancreatic peptide co-secreted with insulin and has been implicated in glucose metabolism and insulin resistance. However, limited data exist regarding serum preptin levels in patients with PCOS. The aim of this study is to evaluate serum preptin levels in women diagnosed with PCOS and to investigate the relationship between preptin levels and insulin resistance parameters.

Participants needed: 60
Trial details
Age: 18-45Biological sex: FemaleType: ObservationalSponsor: GÜLDEN ANATACAUpdated: Jul 30, 2026Duration: 12 Weeks
Eligibility criteria

Female participants aged 18-45 years [+8]

Age <18 years or >45 years [+8]

Status: Not yet recruiting

Evaluation of Neuregulin-4 (NRG4) Levels in Obese and Non-Obese Patients With Type 2 Diabetes Mellitus

This prospective observational study aims to evaluate serum Neuregulin-4 (NRG4) concentrations in obese and non-obese adults with Type 2 Diabetes Mellitus (T2DM) and to investigate their association with obesity status, insulin resistance, and different antidiabetic treatment regimens. Participants will be categorized into five predefined groups according to obesity status and treatment regimen, including SGLT2 inhibitor users, non-SGLT2 oral antidiabetic therapy users, SGLT2 combination therapy users, newly diagnosed treatment-naïve patients, and healthy controls. Clinical, anthropometric, and laboratory parameters including fasting plasma glucose, HbA1c, estimated glomerular filtration rate (eGFR), body mass index, waist circumference, waist-to-hip ratio, and serum NRG4 concentrations will be evaluated. The study aims to determine whether NRG4 may serve as a novel biomarker reflecting metabolic status and treatment response in patients with T2DM.

Participants needed: 125
Trial details
Age: 18-65Biological sex: AllType: ObservationalSponsor: GÜLDEN ANATACAUpdated: Jul 29, 2026Locations: 1Duration: 1 Day
Eligibility criteria

Age 18-65 years [+9]

Age <18 years [+5]

Status: Not yet recruiting

Is Serum Irisin Level a Biomarker in Diabetic Polyneuropathy?

Diabetic polyneuropathy is a common complication of type 2 diabetes mellitus associated with sensory impairment and functional disability. Irisin is a myokine that has been implicated in glucose metabolism and neuroprotection. This prospective observational case-control study aims to evaluate serum irisin concentrations in patients with diabetic polyneuropathy compared with diabetic patients without neuropathy and healthy controls, and to investigate whether serum irisin may serve as a biomarker for diabetic polyneuropathy.

Participants needed: 81
Trial details
Age: 30-75Biological sex: AllType: ObservationalSponsor: GÜLDEN ANATACAUpdated: Jul 29, 2026Locations: 1Duration: 12 Weeks
Eligibility criteria

Age between 30 and 75 years [+3]

Neuropathy due to causes other than diabetes (e.g., vitamin B12 deficiency, chro... [+6]